Medicinal Chemistry of Small-Molecule c-Met Inhibitors: From Approved Therapies to Emerging Multitarget Anticancer Agents. (PubMed, Int J Mol Sci) - Sep 27, 2026 - "The clinical effectiveness of c-Met-targeted treatments such as crizotinib, capmatinib, tepotinib, savolitinib, and cabozantinib has confirmed c-Met as a viable oncogenic driver for therapy, leading to the development of various next-generation inhibitors with different structures...In addition, recent advances in dual- and multitarget agents that simultaneously modulate c-Met and complementary therapeutic targets, including VEGFR-2, EGFR, AXL, MER, PARP1, CDK2, and tubulin, are highlighted as promising strategies for overcoming pathway redundancy and acquired resistance. This review summarizes contemporary structure-based and medicinal chemistry principles underlying c-Met inhibitor discovery, critically evaluates the relationship between biochemical potency and therapeutic efficacy, and provides a framework for the rational design of next-generation c-Met-targeted and multitarget anticancer agents."
Journal • Review • Oncology • Solid Tumor • AXL • CDK2 • EGFR • KDR • PARP1
|
|
Abdelgawad Fahmi; Adel S Girgis; Dalia R Aboshouk; Mariam Abdur-Rahman; Mohamed A Morsy; Mohamed S Bekheit; Siva S Panda; Sudhan Sivakumar
|